Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Cancer Research and TherapeuticsOpen Access

Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYan YiQCQiang CaoHZHongmei Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows neoadjuvant chemoimmunotherapy enhances survival rates in esophageal cancer, indicating effective treatment strategies.

Key Points

  • Neoadjuvant chemoimmunotherapy significantly improved pathological response rates and patient survival.
  • The study included 379 patients and reported a pathological complete response rate of 27.2%.
  • Pathological responses were evaluated using Kaplan–Meier methods with multivariate Cox regression analysis.
  • The findings suggest NICT could transform treatment strategies while maintaining an acceptable safety profile.

Cite This Study

Yi et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64786062https://doi.org/10.4103/jcrt.jcrt_583_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study2025
  2. 2Comparative efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced esophageal squamous cell carcinoma: a dual-center retrospective study2025
  3. 3A meta-analysis based on propensity analysis studies comparing neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma2025
  4. 4Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials2025
  5. 5Research Progress on Neoadjuvant Immunotherapy in Esophageal Squamous Cell Carcinoma2025